In 2006, 39.5 million people were currently infected with HIV, and there were 4.3 million new infections, making HIV one of the greatest health crises in human history. There is a desperate need to develop new methods to prevent HIV infection. The results of three large randomised trials of male circumcision, carried out in South Africa [1], Kenya [2] and Uganda [3], leave no doubt that circumcision more than halves a man’s risk of HIV infection [4,5], and the protective effect is thought to be due to the physical removal of most of the inner foreskin epithelium. This epithelium is richly supplied with Langerhans cells, the main site of HIV entry into the penis [6]. However, Langerhans cells are also a vital part of the body's natural epithelial defence against HIV infection, since they contain the c-type lectin Langerin that normally degrades any virions entering the cell [7,8]. When large amounts of virus are present, the Langerin reserves may be depleted, so that the Langerhans cells instead become vectors for transporting virus to the regional lymph nodes, establishing a systemic infection.
Langerhans cells are also the primary site of HIV entry into the female reproductive tract [9]. It has long been known that the human vaginal epithelium responds to topical oestrogen administration by thickening and keratinization, and vaginal oestrogen cream or tablets are widely used by postmenopausal women to treat vaginal atrophy [10,11]. The vaginal epithelial structure has a direct effect on its susceptibility to HIV infection. A decline in oestrogen levels in women after the menopause is associated with a four to eightfold increased risk of contracting HIV [12].